Literature DB >> 25694313

Randomized controlled trials 5: Determining the sample size and power for clinical trials and cohort studies.

Tom Greene1.   

Abstract

Performing well-powered randomized controlled trials is of fundamental importance in clinical research. The goal of sample size calculations is to assure that statistical power is acceptable while maintaining a small probability of a type I error. This chapter overviews the fundamentals of sample size calculation for standard types of outcomes for two-group studies. It considers (1) the problems of determining the size of the treatment effect that the studies will be designed to detect, (2) the modifications to sample size calculations to account for loss to follow-up and nonadherence, (3) the options when initial calculations indicate that the feasible sample size is insufficient to provide adequate power, and (4) the implication of using multiple primary endpoints. Sample size estimates for longitudinal cohort studies must take account of confounding by baseline factors.

Mesh:

Year:  2015        PMID: 25694313     DOI: 10.1007/978-1-4939-2428-8_13

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  3 in total

1.  Letter to the Editor Regarding "The Effect of Ultrasound-Guided Erector Spinae Plane Block Combined with Dexmedetomidine on Postoperative Analgesia in Patients Undergoing Modified Radical Mastectomy: A Randomized Controlled Trial".

Authors:  Nong He; Fu S Xue; Cheng W Li
Journal:  Pain Ther       Date:  2022-02-25

Review 2.  Reporting quality of randomized controlled trials in otolaryngology: review of adherence to the CONSORT statement.

Authors:  Yu Qing Huang; Katsiaryna Traore; Badr Ibrahim; Maida J Sewitch; Lily H P Nguyen
Journal:  J Otolaryngol Head Neck Surg       Date:  2018-05-15

Review 3.  Use of Photodynamic Therapy Associated with Antimicrobial Peptides for Bacterial Control: A Systematic Review and Meta-Analysis.

Authors:  Luana Mendonça Dias; Túlio Morandin Ferrisse; Karine Sousa Medeiros; Eduardo Maffud Cilli; Ana Claudia Pavarina
Journal:  Int J Mol Sci       Date:  2022-03-17       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.